Comparison the effects and side effects of Covid-19 vaccination in patients with inflammatory bowel disease (IBD): a systematic scoping review
Open Access
- 20 August 2022
- journal article
- review article
- Published by Springer Nature in BMC Gastroenterology
- Vol. 22 (1) , 1-14
Abstract
Covid-19 is a pandemic disease that is more severe and mortal in people with immunodeficiency, such as those with inflammatory bowel disease (IBD). On the other hand, no definitive treatment has been identified for it and the best way to control it is wide spread vaccination. The aim of this study was to evaluate the benefits and side effects of different vaccines in patients with IBD. Three Electronic databases [Medline (accessed from PubMed), Scopus, Science Direct, and Cochrane] were searched systematically without time limit, using MESH terms and the related keywords in English language. We focused on the research studies on the effect and side effects of Covid-19 vaccination in patients with IBD. Articles were excluded if they were not relevant, or were performed on other patients excerpt patients with IBD. Considering the titles and abstracts, unrelated studies were excluded. The full texts of the remained studies were evaluated by authors, independently. Then, the studies' findings were assessed and reported. Finally, after reading the full text of the remained articles, 15 ones included in data extraction. All included studied were research study, and most of them (12/15) had prospective design. Totally, 8/15 studies were performed in single-center settings. In 8/15 studies, patients with IBD were compared with a control group. The results were summarized the in two categories: (1) the effect of vaccination, and (2) side effects. The effect of vaccination were assessed in 13/15 studies. Side effects of Covid-19 vaccination in patients with IBD were reported in 7/15 studies. Patients with IBD can be advised that vaccination may have limited minor side effects, but it can protect them from the serious complications of Covid-19 and its resulting mortality with a high success rate. They should be also mentioned in booster doses.Keywords
All Related Versions
This publication has 28 references indexed in Scilit:
- COVID-19 Vaccination and Inflammatory Bowel Disease: Desired Antibody Responses, Future Directions, and a Note of CautionGastroenterology, 2022
- Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic TherapiesGastroenterology, 2021
- Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2021
- Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients’ SurveyDigestive Diseases and Sciences, 2021
- Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBDGut, 2021
- Does Fellow Participation Increase the Adenoma Detection Rate?Digestive Diseases and Sciences, 2021
- A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID‐19 (SARS‐CoV‐2) pandemicJournal of Medical Virology, 2021
- Review of inflammatory bowel disease and COVID-19World Journal of Gastroenterology, 2020
- StatPearls2020
- PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and ExplanationAnnals of Internal Medicine, 2018